Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 127831, 11 pages
http://dx.doi.org/10.1155/2014/127831
Review Article

Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature

1Department of General Surgery, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430077, China
2Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610, USA
3Department of Rehabilitation, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China
4Department of Medicine and Division of Digestion Disease, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430077, China
5Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong Science and Technology University, Wuhan, Hubei 430030, China

Received 25 June 2014; Revised 21 August 2014; Accepted 8 September 2014; Published 14 October 2014

Academic Editor: Chao Hung Hung

Copyright © 2014 Sheng-Li Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Blechacz and L. Mishra, “Hepatocellular carcinoma biology,” Recent Results in Cancer Research, vol. 190, pp. 1–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of cholestatic liver diseases,” Journal of Hepatology, vol. 51, no. 2, pp. 237–267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Abu El Makarem, “An overview of biomarkers for the diagnosis of hepatocellular carcinoma,” Hepatitis Monthly, vol. 12, no. 10, article e6122, 2012. View at Google Scholar
  6. H.-L. Jia, Q.-H. Ye, L.-X. Qin et al., “Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1133–1139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. P. N. Grozdanov, M. I. Yovchev, and M. D. Dabeva, “The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells,” Laboratory Investigation, vol. 86, no. 12, pp. 1272–1284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Honsová, A. Lodererová, S. Fraňková, M. Oliverius, and P. Trunečka, “Glypican-3 immunostaining significantly improves histoloqical diagnosis of hepatocellular carcinoma,” Casopis Lekaru Ceskych, vol. 150, no. 1, pp. 37–40, 2011. View at Google Scholar · View at Scopus
  9. D. Kandil, G. Leiman, M. Allegretta et al., “Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.,” Cancer, vol. 111, no. 5, pp. 316–322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-P. Yu, X.-G. Xu, R.-J. Ma et al., “Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma,” Journal of Clinical Laboratory Analysis, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. H. J. Lee, J. E. Yeon, S. J. Suh et al., “Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma,” Gut and Liver, vol. 8, no. 2, pp. 177–185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. E. A. E. Badr, T. E. Korah, A. A. Ghani, S. El-Sayed, and S. Badr, “Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis,” Alexandria Journal of Medicine, vol. 50, no. 3, pp. 221–226, 2014. View at Publisher · View at Google Scholar
  13. B. Li, H. Liu, H. W. Shang, P. Li, N. Li, and H. G. Ding, “Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients,” African Health Sciences, vol. 13, no. 3, pp. 703–709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Chen, G. Li, J. Yan et al., “Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma,” Clinica Chimica Acta, vol. 423, pp. 105–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. I. A. Abdelgawad, G. I. Mossallam, N. H. Radwan, H. M. Elzawahry, and N. M. Elhifnawy, “Can glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 12, pp. 7345–7349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. H. O. Gomaa, G. Aboraia, H. Attia, H. Elezawy, E. Nafie, and S. ElBaz, “The diagnostic value of peripheral blood glypican-3 in patients with hepatocellular carcinoma,” World Journal of Medical Sciences, vol. 7, no. 2, pp. 105–112, 2012. View at Google Scholar
  17. W. Wang, L.-J. Zhao, Y. Wang et al., “Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC,” Cancer Biomarkers, vol. 11, no. 1, pp. 29–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S.-S. Qiao, Z.-Q. Cui, L. Gong et al., “Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma,” Hepato-Gastroenterology, vol. 58, no. 110-111, pp. 1718–1724, 2011. View at Google Scholar · View at Scopus
  19. H. A. Abd El Moety, A. A. Abd El Moety, Y. Rostom, and M. El Sawy, “Glypican-3 amino terminal marker for early detection of HCC,” Hepatology International, vol. 5, no. 1, p. 435, 2011. View at Google Scholar
  20. Q. Zhang, Q. Xiao, Z. Lin, X. Ying, Z. Li, and J.-M. Lin, “Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma,” Clinical Biochemistry, vol. 43, no. 12, pp. 1003–1008, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Youssef, S. El-Sharkawy, N. Abbas et al., “Clinical utility of Glypican-3 in hepatocellular carcinoma,” International Journal of Integrative Biology, vol. 10, no. 1, pp. 41–47, 2010. View at Google Scholar
  22. H. Liu, P. Li, Y. Zhai et al., “Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 16, no. 35, pp. 4410–4415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Tangkijvanich, T. Chanmee, S. Komtong et al., “Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers,” Journal of Gastroenterology and Hepatology, vol. 25, no. 1, pp. 129–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Beale, D. Chattopadhyay, J. Gray et al., “AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease,” BMC Cancer, vol. 8, article 200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Hippo, K. Watanabe, A. Watanabe et al., “Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma,” Cancer Research, vol. 64, no. 7, pp. 2418–2423, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Nakatsura, Y. Yoshitake, S. Senju et al., “Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker,” Biochemical and Biophysical Research Communications, vol. 306, no. 1, pp. 16–25, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Capurro, I. R. Wanless, M. Sherman et al., “Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma,” Gastroenterology, vol. 125, no. 1, pp. 89–97, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Wang, H. Yang, H. Xu et al., “Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis,” Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 597–602, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-C. Nault, E. Guyot, C. Laguillier et al., “Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis,” Cancer Epidemiology, Biomarkers & Prevention, vol. 22, no. 8, pp. 1343–1352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Özkan, H. Erdal, E. Koçak et al., “Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma,” Journal of Clinical Laboratory Analysis, vol. 25, no. 5, pp. 350–353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Yasuda, T. Kumada, H. Toyoda et al., “Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma,” Hepatology Research, vol. 40, no. 5, pp. 477–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  34. J. J. Deeks, P. Macaskill, and L. Irwig, “The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed,” Journal of Clinical Epidemiology, vol. 58, no. 9, pp. 882–893, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. F. Altekruse, K. A. Mcglynn, L. A. Dickie, and D. E. Kleiner, “Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008,” Hepatology, vol. 55, no. 2, pp. 476–482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Masuzaki, S. J. Karp, and M. Omata, “New serum markers of hepatocellular carcinoma,” Seminars in Oncology, vol. 39, no. 4, pp. 434–439, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Ho and H. Kim, “Glypican-3: a new target for cancer immunotherapy,” European Journal of Cancer, vol. 47, no. 3, pp. 333–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Tanaka, F. Katayama, H. Kato et al., “Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures,” Journal of Epidemiology, vol. 21, no. 6, pp. 401–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. T.-S. Huang, Y.-C. Shyu, R. Turner, H.-Y. Chen, and P.-J. Chen, “Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol,” Systematic Reviews, vol. 2, article 37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. X.-F. Liu, Z.-D. Hu, X.-C. Liu, Y. Cao, C.-M. Ding, and C.-J. Hu, “Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis,” Clinical Biochemistry, vol. 47, no. 3, pp. 196–200, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Xu, Z. Yan, L. Zhou, and Y. Wang, “A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis,” Journal of Cancer Research and Clinical Oncology, vol. 139, no. 8, pp. 1417–1424, 2013. View at Publisher · View at Google Scholar · View at Scopus